Long term use of disease modifying treatments (DMTs) poses challenges in terms of safety and pharmacoeconomics, while preventing disability progression. As such, there is an ongoing debate on how long disease modifying treatments should be continued and if discontinuation should be considered in stable multiple sclerosis.

 

In this episode, Alan Thompson, Editor in Chief of the MS Journal, speaks with Gilles Edan, Professor of Clinical Neurology and chair of the Department of Neurosciences, University Hospital of Rennes; and Eva Strijbis, neurologist at the Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers.